Recombinant Flu Vaccine Demonstrates Enhanced Immune Response

A collaborative clinical trial has revealed that a recombinant influenza vaccine elicits a significantly stronger immune response against the A(H3N2) flu strain. This particular strain is frequently linked to severe illness and hospitalizations. The results, published in The Lancet Infectious Diseases, suggest the potential for developing more effective influenza vaccines.